Bullish flow detected in Halozyme Therapeutics (HALO), with 5095 calls trading, or 70x the recent avg daily call volume in name. The flow is being led by a buyer of 4750 Jun 10 calls, outright for 15 cents per contact. The position looks opening and comes after a three-day 12 percent move higher in the biotech. Prior to that, shares had plummeted 45.2 percent from the 52-week highs set late-March. Implied vols are up 14 percent to 79 and 5155 Jun 10 calls now traded on the stock. The contract expires at the end of next week.
About the Author (Author Profile)
Frederic Ruffy is a well-known trader, writer, and strategist who has spent years educating investors and creating intelligent, insightful, unbiased market observations that are frequently cited by the Wall Street Journal and other financial publications. As senior analyst, Fred provides frequent and regular notes and daily updates for activity of interest.